Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients (Q33392291)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 14, 2010

Language	Label	Description	Also known as
English	Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients	scientific article published on October 14, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

chromosome abnormality

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

9

object named as

A Tefferi

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

D. Caramazza

1

0000-0002-5903-1034

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

K. H. Begna

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

N. Gangat

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

R. Vaidya

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

S. Siragusa

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

D. L. Van Dyke

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

C. Hanson

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

A. Pardanani

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

full work available at URL

https://www.nature.com/articles/leu2010234.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20944670/pdf/?tool=EBI

Portable Document Format

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20944670/?tool=EBI

online access status

content deliverer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

https://europepmc.org/articles/PMC3035978

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

https://europepmc.org/articles/PMC3035978?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20944670

1 August 2024

http://www.nature.com/articles/leu2010234.pdf

Portable Document Format

1 reference

10.1038/LEU.2010.234

https://api.crossref.org/works/10.1038/LEU.2010.234

1 August 2024

http://www.nature.com/articles/leu2010234

1 reference

10.1038/LEU.2010.234

https://api.crossref.org/works/10.1038/LEU.2010.234

1 August 2024

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

82-88

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Outcome of transplantation for myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Choosing between stem cell therapy and drugs in myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035978

21 June 2018

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Validation of cytogenetic-based risk stratification in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Risk factors for leukemic transformation in patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.234

21 January 2018

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20944670

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2010.234

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33392291&oldid=2220063335"